# US 2025/0084078 A1 · Fused ring-substituted six-membered heterocyclic compound, and preparation method therefor and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084078 A1
- Document ID: US20250084078A1
- Status: Published application
- Kind: A1
- Application number: 18/726,737
- Filed: 2023-01-03
- Published: 2025-03-13
- Earliest claimed: 2022-01-04
- Assignees: Genfleft Therapeutics (Shanghai) Inc.; Zhejiang Genfleft Therapeutics Co., Ltd.
- Applicants: Genfleft Therapeutics (Shanghai) Inc.; Zhejiang Genfleft Therapeutics Co., Ltd.
- Inventors: Jichen ZHAO; Fusheng Zhou; Chonglan LIN; Ling PENG; Wan HE; Huabin YANG; Zhen LI; Tao ZHANG; Kai MA; Jiong LAN; Qiang LU
- Web page: https://patentgrep.com/patent/US20250084078A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/4995: Pyrazines or piperazines forming part of bridged ring systems
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/538: ortho- or peri-condensed with carbocyclic ring systems
- A61K 31/5386: spiro-condensed or forming part of bridged ring systems
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/554: having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A61P 35/00: Antineoplastic agents
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 471/00: Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D 487/00: Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D 487/04: Ortho-condensed systems
- C07D 498/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed in the present invention is a compound as represented by formula (IA) or formula (IC) or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof. The definition of each group in the formula is shown in the description for details. Further disclosed are a pharmaceutical composition containing the compound and the use thereof in the preparation of a drug for preventing and/or treating diseases or conditions related to HPK1 activity.

## Claims

### Claim 1

A compound of formula (IA), or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof:
wherein
Y is CH or N;
R1 is H, C1-6 alkyl, —C1-4 alkyl-hydroxy, —C1-4 alkyl-cyano, —C1-4 alkyl-carboxy, —C1-4 alkyl-C1-6 alkyl, —C1-4 alkyl-C1-6 alkoxy, C3-20 cycloalkyl, 3- to 20-membered heterocyclyl, C6-14 aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-C3-20 cycloalkyl, —C1-4 alkyl-O—C3-20 cycloalkyl, —C1-4 alkyl-3- to 20-membered heterocyclyl, —C1-4 alkyl-O-3- to 20-membered heterocyclyl, —C1-4 alkyl-C6-14 aryl, —C1-4 alkyl-O—C6-14 aryl, —C1-4 alkyl-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-O-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-O-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-NRaRb, —C1-4 alkyl-NRd—C(═O)—Rc, —C1-4 alkyl-NRd—C(═O)—NRaRb, —C1-4 alkyl-NRd—S(═O)2—Rc, —C1-4 alkyl-NRd—S(═O)2—NRaRb, —C1-4 alkyl-C(═O)—NRaRb, —C1-4 alkyl-S(═O)2—Rc, —C1-4 alkyl-S(═O)2—NRaRb, —C(═O)—C1-6 alkyl, —C(═O)—C3-20 cycloalkyl, —C(═O)-3- to 20-membered heterocyclyl, —C(═O)—C6-14 aryl, —C(═O)-5- or 6-membered monocyclic heteroaryl, —C(═O)-8- to 10-membered bicyclic heteroaryl, —C(═O)—NRaRb, —S(═O)2—Rc, or —S(═O)2—NRaRb; wherein the C1-6 alkyl and the C1-6 alkoxy are each independently optionally substituted with halogen, deuterium, cyano, or hydroxyl; the C3-20 cycloalkyl, the 3- to 20-membered heterocyclyl, the C6-14 aryl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from group S1; the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl each independently contains 1, 2, 3, or 4 heteroatom(s) independently selected from N, O, and S as ring atoms;
Z, L1 and R4 are selected from one of the following combinations:
(a) Z is N; -L1-R4 is absent;
(b) Z is C;
L1 is a bond, —C1-4 alkyl-, —C3-6 monocyclic cycloalkyl-, —O—, —S—, —NH—, —C(═O)—, —S(═O)—, or —S(═O)2—;
R4 is selected from the group consisting of H, halogen, cyano, hydroxyl, carboxyl, nitro, C1-6 alkyl, C1-6 alkoxy, C3-20 cycloalkyl, 3- to 20-membered heterocyclyl, C6-14 aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-hydroxyl, —C1-4 alkyl-cyano, —C1-4 alkyl-carboxyl, —C1-4 alkyl-C1-6 alkyl, —C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-C3-20 cycloalkyl, —C1-4 alkyl-O—C3-20 cycloalkyl, —C1-4 alkyl-3- to 20-membered heterocyclyl, —C1-4 alkyl-O-3- to 20-membered heterocyclyl, —C1-4 alkyl-C6-14 aryl, —C1-4 alkyl-O—C6-14 aryl, —C1-4 alkyl-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-O-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-O-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-NRaRb, —C1-4 alkyl-C(═O)—NRaRb, —C1-4 alkyl-NRd—C(═O)—Rc, —C1-4 alkyl-NRd—C(═O)—NRaRb, —C1-4 alkyl-S(═O)2—Rc, —C1-4 alkyl-NRd—S(═O)2—Rc, —C1-4 alkyl-S(═O)2—NRaRb, —C1-4 alkyl-NRd—S(═O)2—NRaRb, —C(═O)—C1-6 alkyl, —C(═O)—C3-20 cycloalkyl, —C(═O)-3- to 20-membered heterocyclyl, —C(═O)—C6-14 aryl, —C(═O)-5- or 6-membered monocyclic heteroaryl, —C(═O)-8- to 10-membered bicyclic heteroaryl, —C(═O)—NRaRb, —NRd—C(═O)—Rc, —NRd—C(═O)—NRaRb, —S(═O)2—Rc, —NRd—S(═O)2—Rc, —S(═O)2—NRaRb, —NRd—S(═O)2—NRaRb, —NRaRb, —ORc; the C1-6 alkyl and the C1-6 alkoxy are each independently optionally substituted with halogen, deuterium, cyano, or hydroxy; the C3-20 cycloalkyl, the 3- to 20-membered heterocyclyl, the C6-14 aryl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from group S1; the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl each independently contains 1, 2, 3, or 4 heteroatom(s) independently selected from N, O, and S as ring atoms;
is phenyl or 5- or 6-membered monocyclic heteroaryl; the 5- or 6-membered monocyclic heteroaryl contains 1, 2, or 3 heteroatom(s) independently selected from N, O, and S as ring atoms;
the phenyl or the 5- or 6-membered monocyclic heteroaryl are each independently optionally substituted with m1 R2 group(s); m1 is 1, 2, 3, or 4;
the R2 is
wherein
R2a is H, deuterium, C1-6 alkyl, phenyl, or deuterated C1-6 alkyl, and R2b is H, deuterium, C1-6 alkyl, or deuterated C1-6 alkyl; or R2a and R2b together with the carbon atom to which the R2a and R2b are attached form a C3-6 monocyclic cycloalkyl group; and the bond between R2a and the carbon atom is a single bond; R2c is H, deuterium, C1-6 alkyl, deuterated C1-6 alkyl, —C1-4 alkyl-C3-6 monocyclic cycloalkyl, or C3-6 monocyclic cycloalkyl; R2d is H, deuterium, C1-6 alkyl, deuterated C1-6 alkyl, C3-20 cycloalkyl, or 3- to 20-membered heterocyclyl; or
when R2a and R2d together with the nitrogen atom to which the R2a and R2d are attached form a 3- to 20-membered heterocyclyl group, a 5- or 6-membered monocyclic heteroaryl group, or an 8- to 10-membered bicyclic heteroaryl group, R2c is H, deuterium, C1-6 alkyl, or deuterated C1-6 alkyl; R2b is H, deuterium, C1-6 alkyl, or deuterated C1-6 alkyl, and the bond between R2a and the carbon atom is a single bond; or R2b is absent, and the bond between R2a and the carbon atom is a double bond; the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl, or the 8- to 10-membered bicyclic heteroaryl each independently contains one nitrogen atom and optionally 1 or 2 heteroatom(s) independently selected from N, O, and S as ring atoms; and the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl and the 8- to 10-membered bicyclic heteroaryl are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from group S1; or
when R2c and R2d together with the nitrogen atom to which the R2c and R2d are attached form a 3- to 20-membered heterocyclyl group, a 5- or 6-membered monocyclic heteroaryl group, or an 8- to 10-membered bicyclic heteroaryl group, R2a is H, deuterium, C1-6 alkyl, or deuterated C1-6 alkyl, R2b is H, deuterium, C1-6 alkyl, or deuterated C1-6 alkyl, and the bond between R2a and the carbon atom is a single bond; the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl, or the 8- to 10-membered bicyclic heteroaryl each independently contains one nitrogen atom and optionally 1 or 2 heteroatom(s) independently selected from N, O, and S as ring atoms; and the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl and the 8- to 10-membered bicyclic heteroaryl are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from group S1; or
the R2 is
is 3- to 20-membered heterocyclyl, 5- or 6-membered monocyclic heteroaryl, or 8- to 10-membered bicyclic heteroaryl containing one nitrogen atom and attached to other moieties of a molecule through the nitrogen atom;
further optionally contains 1 or 2 heteroatom(s) independently selected from N, O, and S as ring atoms; the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl and the 8- to 10-membered bicyclic heteroaryl are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from group S1;
is phenyl or 5- or 6-membered monocyclic heteroaryl; the 5- or 6-membered monocyclic heteroaryl contains 1, 2, or 3 heteroatom(s) independently selected from N, O, and S as ring atoms; the phenyl and the 5- or 6-membered monocyclic heteroaryl are each independently optionally substituted with m2 R3 group(s);
m2 is 1, 2, 3, or 4; each R3 is independently selected from the group consisting of H, oxo (═O), halogen, cyano, hydroxyl, carboxyl, nitro, C1-6 alkyl, C1-6 alkoxy, C3-20 cycloalkyl, 3- to 20-membered heterocyclyl, C6-14 aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, —O—C3-20 cycloalkyl, —O-3- to 20-membered heterocyclyl, —O—C6-14 aryl, —O-5- or 6-membered monocyclic heteroaryl, —O-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-hydroxyl, —C1-4 alkyl-cyano, —C1-4 alkyl-C1-6 alkyl, —C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-C3-20 cycloalkyl, —C1-4 alkyl-O—C3-20 cycloalkyl, —C1-4 alkyl-3- to 20-membered heterocyclyl, —C1-4 alkyl-O-3- to 20-membered heterocyclyl, —C1-4 alkyl-C6-14 aryl, —C1-4 alkyl-O—C6-14 aryl, —C1-4 alkyl-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-O-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-O-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-NRaRb, —C1-4 alkyl-C(═O)—NRaRb, —C1-4 alkyl-NRd—C(═O)—Rc, —C1-4 alkyl-NRd—C(═O)—NRaRb, —C1-4 alkyl-S(═O)2—Rc, —C1-4 alkyl-NRd—S(═O)2—Rc, —C1-4 alkyl-S(═O)2—NRaRb, —C1-4 alkyl-NRd—S(═O)2—NRaRb, —C1-4 alkyl-carboxy, —C(═O)—C1-6 alkyl, —C(═O)O—C1-6 alkyl, —C(═O)—C1-4 alkyl-hydroxy, —C(═O)—C1-4 alkyl-C1-6 alkoxy, —C(═O)—C1-4 alkyl-O—C3-20 cycloalkyl, —C(═O)—C3-20 cycloalkyl, —C(═O)O—C3-20 cycloalkyl, —C(═O)—C1-4 alkyl-C3-20 cycloalkyl, —C(═O)-3- to 20-membered heterocyclyl, —C(═O)—C1-4 alkyl-3- to 20-membered heterocyclyl, —C(═O)—C6-14 aryl, —C(═O)-5- or 6-membered monocyclic heteroaryl, —C(═O)-8- to 10-membered bicyclic heteroaryl, —C(═O)—NRaRb, —NRd—C(═O)—Rc, —NRd—C(═O)—NRaRb, —S(═O)2—Rc, —NRd—S(═O)2—Rc, —S(═O)2—NRaRb, —NRd—S(═O)2—NRaRb, —NRaRb, —ORc, —C1-4 alkyl-P(═O)(C1-6 alkyl)2, —P(═O)(C1-6 alkyl)2; wherein the C1-6 alkyl and the C1-6 alkoxy are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from halogen, deuterium, cyano, 5- to 6-membered heterocyclyl, and hydroxyl; the C3-20 cycloalkyl, the 3- to 20-membered heterocyclyl, the C6-14 aryl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from group S2; the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl each independently contains 1, 2, 3, or 4 heteroatom(s) independently selected from N, O, and S as ring atoms; or
is C5-7 monocyclic cycloalkyl or 5-, 6- or 7-membered monocyclic heterocyclyl; the 5-, 6- or 7-membered heterocyclyl each independently contains 1, 2, or 3 heteroatom(s) independently selected from N, O, and S as ring atoms; the C5-7 monocyclic cycloalkyl and the 5-, 6- or 7-membered monocyclic heterocyclyl are each independently optionally substituted with m2 R3 group(s);
m2 is 1, 2, 3, or 4; each R3 is independently selected from the group consisting of H, oxo (═O), halogen, cyano, hydroxyl, carboxyl, nitro, C1-6 alkyl, C1-6 alkoxy, C3-20 cycloalkyl, 3- to 20-membered heterocyclyl, C6-14 aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, —O—C3-20 cycloalkyl, —O-3- to 20-membered heterocyclyl, —O—C6-14 aryl, —O-5- or 6-membered monocyclic heteroaryl, —O-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-hydroxyl, —C1-4 alkyl-cyano, —C1-4 alkyl-C1-6 alkyl, —C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-C3-20 cycloalkyl, —C1-4 alkyl-O—C3-20 cycloalkyl, —C1-4 alkyl-3- to 20-membered heterocyclyl, —C1-4 alkyl-O-3- to 20-membered heterocyclyl, —C1-4 alkyl-C6-14 aryl, —C1-4 alkyl-O—C6-14 aryl, —C1-4 alkyl-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-O-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-O-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-NRaRb, —C1-4 alkyl-C(═O)—NRaRb, —C1-4 alkyl-NRd—C(═O)—Rc, —C1-4 alkyl-NRd—C(═O)—NRaRb, —C1-4 alkyl-S(═O)2—Rc, —C1-4 alkyl-NRd—S(═O)2—Rc, —C1-4 alkyl-S(═O)2—NRaRb, —C1-4 alkyl-NRd—S(═O)2—NRaRb, —C1-4 alkyl-carboxy, —C(═O)—C1-6 alkyl, —C(═O)O—C1-6 alkyl, —C(═O)—C1-4 alkyl-hydroxy, —C(═O)—C1-4 alkyl-C1-6 alkoxy, —C(═O)—C1-4 alkyl-O—C3-20 cycloalkyl, —C(═O)—C3-20 cycloalkyl, —C(═O)O—C3-20 cycloalkyl, —C(═O)—C1-4 alkyl-C3-20 cycloalkyl, —C(═O)-3- to 20-membered heterocyclyl, —C(═O)—C1-4 alkyl-3- to 20-membered heterocyclyl, —C(═O)—C6-14 aryl, —C(═O)-5- or 6-membered monocyclic heteroaryl, —C(═O)-8- to 10-membered bicyclic heteroaryl, —C(═O)—NRaRb, —NRd—C(═O)—Rc, —NRd—C(═O)—NRaRb, —S(═O)2—Rc, —NRd—S(═O)2—Rc, —S(═O)2—NRaRb, —NRd—S(═O)2—NRaRb, —NRaRb, —ORc, —C1-4 alkyl-P(═O)(C1-6 alkyl)2, —P(═O)(C1-6 alkyl)2, ═CR3aR3b; wherein two hydrogen atoms attached to a same carbon atom can be substituted with two R3 groups such that the two R3 groups together with the carbon atom to which the two R3 groups are attached form a C3-6 monocyclic cycloalkyl group or a 3- to 6-membered monocyclic heterocyclyl group; or two hydrogen atoms attached to different carbon atoms are substituted with two R3 groups, and the two R3 groups join to form —CH2—, —CH2CH2—, or —CH2CH2CH2—; wherein the C1-6 alkyl and the C1-6 alkoxy are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from halogen, deuterium, cyano, 5- to 6-membered heterocyclyl, and hydroxyl; the C3-20 cycloalkyl, the 3- to 20-membered heterocyclyl, the C6-14 aryl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from group S2; the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl each independently contains 1, 2, 3, or 4 heteroatom(s) independently selected from N, O, and S as ring atoms;
wherein R3a and R3b are each independently hydrogen, halogen, cyano, C1-6 alkyl, halogenated C1-6 alkyl, C6-14 aryl, or 5- or 6-membered monocyclic heteroaryl; the C6-14 aryl or the 5- or 6-membered monocyclic heteroaryl is optionally substituted with 1, 2, or 3 group(s) selected from halogen, cyano, C1-4 alkyl, C1-4 alkoxy, halogenated C1-4 alkyl, halogenated C1-4 alkoxy; or R3a and R3b together with the carbon atom to which the R3a and R3b are attached form a C3-6 monocyclic cycloalkyl group or a 3- to 6-membered monocyclic heterocyclyl group; the C3-6 monocyclic cycloalkyl or the 3- to 6-membered monocyclic heterocyclyl is optionally substituted with 1, 2, or 3 group(s) selected from halogen, cyano, C1-4 alkyl, C1-4 alkoxy, halogenated C1-4 alkyl, halogenated C1-4 alkoxy, C6-14 aryl, 5- or 6-membered monocyclic heteroaryl;
among the above groups, each group from group S1 is independently selected from the group consisting of oxo (═O), halogen, cyano, hydroxyl, carboxyl, nitro, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C3-20 cycloalkyl, 3- to 20-membered heterocyclyl, C6-14 aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, —O—C3-20 cycloalkyl, —O-3- to 20-membered heterocyclyl, —O—C6-14 aryl, —O-5- or 6-membered monocyclic heteroaryl, —O-8- to 10-membered bicyclic heteroaryl, —C≡C—C3-20 cycloalkyl, —C≡C-3- to 20-membered heterocyclyl, —C≡C—C6-14 aryl, —C≡C-5- or 6-membered monocyclic heteroaryl, —C≡C-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-hydroxy, —C1-4 alkyl-cyano, —C1-4 alkyl-C1-6 alkyl, —C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-C3-20 cycloalkyl, —C1-4 alkyl-O—C3-20 cycloalkyl, —C1-4 alkyl-3- to 20-membered heterocyclyl, —C1-4 alkyl-O-3- to 20-membered heterocyclyl, —C1-4 alkyl-C6-14 aryl, —C1-4 alkyl-O—C6-14 aryl, —C1-4 alkyl-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-O-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-O-8- to 10-membered bicyclic heteroaryl, —S(═O)2—C1-6 alkyl, —S(═O)2—C3-20 cycloalkyl, —S(═O)2-3- to 20-membered heterocyclyl, —S(═O)2-5- or 6-membered monocyclic heteroaryl, —S(═O)2-8- to 10-membered bicyclic heteroaryl, —C(═O)O—C1-6 alkyl, —C(═O)O—C3-20 cycloalkyl, —C(═O)O-3- to 20-membered heterocyclyl, —C(═O)O-5- or 6-membered monocyclic heteroaryl, —C(═O)O-8- to 10-membered bicyclic heteroaryl, —C(═O)—C1-6 alkyl, —C(═O)—C3-20 cycloalkyl, —C(═O)—C6-14 aryl, —NRa1Rb1, —C(═O)—NRa1Rb1, —ORc1, —C1-4 alkyl-S(═O)2—C1-6 alkyl, —C1-4 alkyl-S(═O)2—C3-20 cycloalkyl, —C1-4 alkyl-S(═O)2-3- to 20-membered heterocyclyl, —C1-4 alkyl-C(═O)O—C1-6 alkyl, —C1-4 alkyl-C(═O)O—C3-20 cycloalkyl, —C1-4 alkyl-C(═O)—C1-6 alkyl, —C1-4 alkyl-C(═O)—C3-20 cycloalkyl, —C1-4 alkyl-C(═O)—C6-14 aryl, —C(═O)-5- or 6-membered monocyclic heteroaryl, —C(═O)-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-NRa1Rb1, —C1-4 alkyl-C(═O)—NRa1Rb1, —C≡C—C(═O)—NRa1Rb1, —C≡C—C1-4 alkyl-C(═O)—NRa1Rb1, —C1-4 alkyl-ORc1, —C1-4 alkyl-P(═O)—(C1-6 alkyl)2, —P(═O)—(C1-6 alkyl)2, —C1-4 alkyl-NRd1—C(═O)—Rc1, —C1-4 alkyl-NRd1—C(═O)—NRa1Rb1, —C1-4 alkyl-NRd1—S(═O)2—Rc1, —C1-4 alkyl-S(═O)2—NRa1Rb1, —C1-4 alkyl-NRd1—S(═O)2—NRa1Rb1—NRd1—C(═O)—Rc1, —NRd1—C(═O)—NRa1Rb1, —NRd1—S(═O)2—Rc1, —S(═O)2—NRa1Rb1, —NRd1—S(═O)2—NRa1Rb1; wherein the C1-6 alkyl, the C1-6 alkoxy, the C2-6 alkenyl, and the C2-6 alkynyl are each independently optionally substituted with 1, 2, or 3 group(s) selected from halogen, deuterium, cyano, or hydroxyl; the C3-20 cycloalkyl, the 3- to 20-membered heterocyclyl, the C6-14 aryl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from group S3; the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl each independently contains 1, 2, 3, or 4 heteroatom(s) independently selected from N, O, and S as ring atoms;
among the above groups, each group from group S2 is independently selected from the group consisting of oxo (═O), halogen, cyano, hydroxyl, carboxyl, nitro, C1-6 alkyl, C2-6 alkynyl, C1-6 alkoxy, C3-20 cycloalkyl, 3- to 20-membered heterocyclyl, C6-14 aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, —O-3- to 20-membered heterocyclyl, —O-5- or 6-membered monocyclic heteroaryl, —O-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-hydroxyl, —C1-4 alkyl-cyano, —C1-4 alkyl-C1-6 alkyl, —C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-C3-20 cycloalkyl, —C1-4 alkyl-O—C3-20 cycloalkyl, —C1-4 alkyl-3- to 20-membered heterocyclyl, —C1-4 alkyl-O-3- to 20-membered heterocyclyl, —C1-4 alkyl-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-O-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-O-8- to 10-membered bicyclic heteroaryl, —S(═O)2—C1-6 alkyl, —S(═O)2—C3-20 cycloalkyl, —S(═O)2-3- to 20-membered heterocyclyl, —S(═O)2-5- or 6-membered monocyclic heteroaryl, —S(═O)2-8- to 10-membered bicyclic heteroaryl, —C(═O)O—C1-6 alkyl, —C(═O)O—C3-20 cycloalkyl, —C(═O)O-3- to 20-membered heterocyclyl, —C(═O)O-5- or 6-membered monocyclic heteroaryl, —C(═O)O-8- to 10-membered bicyclic heteroaryl, —NRa1Rb1, —C(═O)—NRa1Rb1, —ORc1—C1-4 alkyl-C(═O)O—C1-6 alkyl, —C1-4 alkyl-C(═O)O—C3-20 cycloalkyl, —C1-4 alkyl-NRa1Rb1, —C1-4 alkyl-C(═O)—NRa1Rb1, —C≡C—C(═O)—NRa1Rb1, —C≡C—C1-4 alkyl-C(═O)—NRa1Rb1, —C1-4 alkyl-ORc1, —C1-4 alkyl-P(═O)—(C1-6 alkyl)2, —P(═O)—(C1-6 alkyl)2, —C1-4 alkyl-NRd1—C(═O)—Rc1, —C1-4 alkyl-NRd1—C(═O)—NRa1Rb1, —C1-4 alkyl-NRd1—S(═O)2—Rc1, —C1-4 alkyl-S(═O)2—NRa1Rb1, —C1-4 alkyl-NRd1—S(═O)2—NRa1Rb1, —NRd1—C(═O)—Rc1, —NRd1—C(═O)—NRa1Rb1, —NRd1—S(═O)2—Rc1, —S(═O)2—NRa1Rb1, —NRd1—S(═O)2—NRa1Rb1; wherein the C1-6 alkyl, the C1-6 alkoxy, and the C2-6 alkynyl are each independently optionally substituted with 1, 2, or 3 group(s) selected from halogen, deuterium, cyano, or hydroxyl; the C3-20 cycloalkyl, the 3- to 20-membered heterocyclyl, the C6-14 aryl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from group S3; the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl each independently contains 1, 2, 3, or 4 heteroatom(s) independently selected from N, O, and S as ring atoms;
among the above groups, each Ra, Rb, Ra1, and Rb1 is independently H, C1-6 alkyl, halogenated C1-6 alkyl, deuterated C1-6 alkyl, —C1-4 alkyl-hydroxy, —C1-4 alkyl-cyano, —C1-4 alkyl-halogenated C1-6 alkyl, —C1-4 alkyl-deuterated C1-6 alkyl, —C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-halogenated C1-6 alkoxy, —C1-4 alkyl-deuterated C1-6 alkoxy, C3-6 monocyclic cycloalkyl, —C1-4 alkyl-C3-6 monocyclic cycloalkyl, —C1-4 alkyl-O—C3-6 monocyclic cycloalkyl, 3- to 6-membered monocyclic heterocyclyl, —C1-4 alkyl-3- to 6-membered monocyclic heterocyclyl, —C1-4 alkyl-O-3- to 6-membered monocyclic heterocyclyl, phenyl, —C1-4 alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-8- to 10-membered bicyclic heteroaryl, —S(═O)2—C1-6 alkyl, —S(═O)2—C3-6 monocyclic cycloalkyl, —S(═O)2-3- to 6-membered monocyclic heterocyclyl, —C(═O)—C1-6 alkyl, —C(═O)—C3-6 monocyclic cycloalkyl, —C(═O)-3- to 6-membered monocyclic heterocyclyl; wherein the C3-6 monocyclic cycloalkyl, the 3- to 6-membered monocyclic heterocyclyl, the phenyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are optionally substituted with 1 or 2 group(s) selected from the group consisting of halogen, hydroxyl, carboxyl, nitro, C1-6 alkyl, halogenated C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkoxy, deuterated C1-6 alkoxy, —NH2, —NHC1-6 alkyl, —N(C1-6 alkyl)2, —C1-4 alkyl-P(═O)—(C1-6 alkyl)2, —P(═O)—(C1-6 alkyl)2; or
each Ra and Rb together with the nitrogen atom to which the Ra and Rb are attached form a 3- to 20-membered heterocyclyl group; each Ra1 and Rb1 together with the nitrogen atom to which the Ra1 and Rb1 are attached form a 3- to 20-membered heterocyclyl group; wherein the 3- to 20-membered heterocyclyl is each independently optionally substituted with 1 or 2 group(s) selected from the group consisting of halogen, hydroxyl, carboxyl, nitro, C1-6 alkyl, halogenated C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkoxy, deuterated C1-6 alkoxy, —NH2, —NHC1-6 alkyl, —N(C1-6 alkyl)2, —C1-4 alkyl-P(═O)—(C1-6 alkyl)2, —P(═O)—(C1-6 alkyl)2;
among the above groups, each Rd and Rd1 are independently H, C1-6 alkyl, or deuterated C1-6 alkyl;
among the above groups, each Rc and Rc1 are independently H, C1-6 alkyl, halogenated C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkoxy, deuterated C1-6 alkoxy, —C1-4 alkyl-halogenated C1-6 alkyl, —C1-4 alkyl-deuterated C1-6 alkyl, —C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-halogenated C1-6 alkoxy, —C1-4 alkyl-deuterated C1-6 alkoxy, C3-6 monocyclic cycloalkyl, —C1-4 alkyl-C3-6 monocyclic cycloalkyl, —C1-4 alkyl-O—C3-6 monocyclic cycloalkyl, 3- to 6-membered monocyclic heterocyclyl, —C1-4 alkyl-3- to 6-membered monocyclic heterocyclyl, —C1-4 alkyl-O-3- to 6-membered monocyclic heterocyclyl, phenyl, —C1-4 alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, or —C1-4 alkyl-8- to 10-membered bicyclic heteroaryl; the C3-6 monocyclic cycloalkyl, the 3- to 6-membered monocyclic heterocyclyl, the phenyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are optionally substituted with 1 or 2 group(s) selected from the group consisting of halogen, hydroxyl, carboxyl, nitro, C1-6 alkyl, halogenated C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkoxy, deuterated C1-6 alkoxy, —NH2, —NHC1-6 alkyl, —N(C1-6 alkyl)2, —C1-4 alkyl-P(═O)—(C1-6 alkyl)2, —P(═O)—(C1-6 alkyl)2;
among the above groups, each group from group S3 is independently selected from the group consisting of oxo (C═O), cyano, halogen, hydroxy, carboxy, nitro, C1-6 alkyl, halogenated C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkoxy, deuterated C1-6 alkoxy, —NH2, —NHC1-6 alkyl, —N(C1-6 alkyl)2, —C1-4 alkyl-P(═O)—(C1-6 alkyl)2, —P(═O)—(C1-6 alkyl)2, 3- to 6-membered monocyclic heterocyclyl;
among the above groups, the —C1-4 alkyl- or the —C3-6 monocyclic cycloalkyl- is unsubstituted; or
hydrogen atoms of the —C1-4 alkyl- are each independently substituted with a group selected from halogen, cyano, hydroxy, C1-6 alkyl, halogenated C1-6 alkyl, deuterated C1-6 alkyl, —CH2-hydroxy, —CH2-cyano, and phenyl, or two hydrogen atoms attached to a same carbon atom of the C1-4 alkyl are simultaneously substituted with —(CH2)j— to form a cycloalkyl group, wherein j is 2, 3, 4, 5, or 6; hydrogen atoms of the —C3-6 monocyclic cycloalkyl- are each independently substituted with a group selected from halogen, cyano, hydroxy, C1-6 alkyl, halogenated C1-6 alkyl, deuterated C1-6 alkyl.

### Claim 2 (depends on 1)

The compound, or the pharmaceutically acceptable salt, the stereoisomer, the solvate or the prodrug thereof of claim 1, wherein the compound is a compound of formula (IA-1);
wherein R1, Y,
R2, m1,
R3, and m2 are as defined in claim 1;
L1 is a bond, —C1-4 alkyl-, —C3-6 monocyclic cycloalkyl-, —O—, —S—, —NH—, —C(═O)—, —S(═O)—, or —S(═O)2—;
R4 is selected from the group consisting of H, halogen, cyano, hydroxyl, carboxyl, nitro, C1-6 alkyl, C1-6 alkoxy, C3-20 cycloalkyl, 3- to 20-membered heterocyclyl, C6-14 aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-hydroxyl, —C1-4 alkyl-cyano, —C1-4 alkyl-carboxyl, —C1-4 alkyl-C1-6 alkyl, —C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-C3-20 cycloalkyl, —C1-4 alkyl-O—C3-20 cycloalkyl, —C1-4 alkyl-3- to 20-membered heterocyclyl, —C1-4 alkyl-O-3- to 20-membered heterocyclyl, —C1-4 alkyl-C6-14 aryl, —C1-4 alkyl-O—C6-14 aryl, —C1-4 alkyl-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-O-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-O-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-NRaRb, —C1-4 alkyl-C(═O)—NRaRb, —C1-4 alkyl-NRd—C(═O)—Rc, —C1-4 alkyl-NRd—C(═O)—NRaRb, —C1-4 alkyl-S(═O)2—Rc, —C1-4 alkyl-NRd—S(═O)2—Rc, —C1-4 alkyl-S(═O)2—NRaRb, —C1-4 alkyl-NRd—S(═O)2—NRaRb, —C(═O)—C1-6 alkyl, —C(═O)—C3-20 cycloalkyl, —C(═O)-3- to 20-membered heterocyclyl, —C(═O)—C6-14 aryl, —C(═O)-5- or 6-membered monocyclic heteroaryl, —C(═O)-8- to 10-membered bicyclic heteroaryl, —C(═O)—NRaRb, —NRd—C(═O)—Rc, —NRd—C(═O)—NRaRb, —S(═O)2—Rc, —NRd—S(═O)2—Rc, —S(═O)2—NRaRb, —NRd—S(═O)2—NRaRb, —NRaRb, —ORc; the C1-6 alkyl and the C1-6 alkoxy are each independently optionally substituted with halogen, deuterium, cyano, or hydroxy; the C3-20 cycloalkyl, the 3- to 20-membered heterocyclyl, the C6-14 aryl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from group S1; the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl each independently contains 1, 2, 3, or 4 heteroatom(s) independently selected from N, O, and S as ring atoms;
wherein Ra, Rb, Rc, Rd, and group S1 are each as defined in claim 1.

### Claim 3 (depends on 1)

The compound, or the pharmaceutically acceptable salt, the stereoisomer, the solvate or the prodrug thereof of claim 1, wherein the compound is a compound of formula (IA1), a compound of formula (IA2), a compound of formula (IA3), a compound of formula (IA4), a compound of formula (IA5), or a compound of formula (IA6);
in each formula, Y, L1, R1, R2,
R3, R4, and m2 are each independently as defined in claim 1.

### Claim 4 (depends on 1)

The compound, or the pharmaceutically acceptable salt, the stereoisomer, the solvate or the prodrug thereof of claim 1, wherein the compound is a compound of formula (IB);
wherein R1,
R2, m1,
R3, and m2 are as defined in claim 1.

### Claim 5 (depends on 4)

The compound, or the pharmaceutically acceptable salt, the stereoisomer, the solvate or the prodrug thereof of claim 4, wherein the compound is a compound of formula (IB1), a compound of formula (IB2), a compound of formula (IB3), a compound of formula (IB4), a compound of formula (IB5), or a compound of formula IB6);
in each formula, R1, R2,
R3, and m2 are each independently as defined in claim 4.

### Claim 6 (depends on 1)

The compound, or the pharmaceutically acceptable salt, the stereoisomer, the solvate or the prodrug thereof of claim 1, wherein
R1 is
wherein R1a is C1-6 alkyl, halogenated C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkoxy, deuterated C1-6 alkoxy, —C1-4 alkyl-hydroxy, —C1-4 alkyl-cyano, —C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-halogenated C1-6 alkoxy, or —C1-4 alkyl-deuterated C1-6 alkoxy;
R1b is H, halogen, C1-3 alkyl, halogenated C1-3 alkyl, deuterated C1-3 alkyl, C1-3 alkoxy, halogenated C1-3 alkoxy, or deuterated C1-3 alkoxy;
or
R1 is
wherein R1a is C3-6 monocyclic cycloalkyl, 3- to 6-membered monocyclic heterocyclyl, phenyl, 5- or 6-membered monocyclic heteroaryl, or 8- to 10-membered bicyclic heteroaryl; R1b is H, halogen, C1-3 alkyl, halogenated C1-3 alkyl, deuterated C1-3 alkyl, C1-3 alkoxy, halogenated C1-3 alkoxy, or deuterated C1-3 alkoxy; wherein the C3-6 monocyclic cycloalkyl, the 3- to 6-membered monocyclic heterocyclyl, the phenyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from group S1.

### Claim 7

A compound of formula (IC), or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof:
wherein
X is CR5 or N; Y is CH or N; and X and Y cannot both be N; R5 is H, C1-6 alkyl, or C3-6 monocyclic cycloalkyl;
is phenyl or 5- or 6-membered monocyclic heteroaryl; the 5- or 6-membered monocyclic heteroaryl contains 1, 2, or 3 heteroatom(s) independently selected from N, O, and S as ring atoms; the phenyl or the 5- or 6-membered monocyclic heteroaryl are each independently optionally substituted with m1 R2 group(s); m1 is 1, 2, 3, or 4;
the R2 is
wherein
R2a is H, deuterium, C1-6 alkyl, phenyl, or deuterated C1-6 alkyl, and R2b is H, deuterium, C1-6 alkyl, or deuterated C1-6 alkyl; or R2a and R2b together with the carbon atom to which the R2a and R2b are attached form a C3-6 monocyclic cycloalkyl group, and a bond between R2a and the carbon atom is a single bond; R2c is H, deuterium, C1-6 alkyl, deuterated C1-6 alkyl, —C1-4 alkyl-C3-6 monocyclic cycloalkyl, or C3-6 monocyclic cycloalkyl; R2d is H, deuterium, C1-6 alkyl, deuterated C1-6 alkyl, C3-20 cycloalkyl, or 3- to 20-membered heterocyclyl; or
when R2a and R2d together with the nitrogen atom to which the R2a and R2d are attached form a 3- to 20-membered heterocyclyl group, a 5- or 6-membered monocyclic heteroaryl group, or an 8- to 10-membered bicyclic heteroaryl group, R2c is H, deuterium, C1-6 alkyl, or deuterated C1-6 alkyl; R2b is H, deuterium, C1-6 alkyl, or deuterated C1-6 alkyl, and the bond between R2a and the carbon atom is a single bond; or R2b is absent, and the bond between R2a and the carbon atom is a double bond; the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl, or the 8- to 10-membered bicyclic heteroaryl each independently contains one nitrogen atom and optionally 1 or 2 heteroatom(s) independently selected from N, O, and S as ring atoms; and the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from group S1; or
when R2c and R2d together with the nitrogen atom to which the R2c and R2d are attached form a 3- to 20-membered heterocyclyl group, a 5- or 6-membered monocyclic heteroaryl group, or an 8- to 10-membered bicyclic heteroaryl group, R2a is H, deuterium, C1-6 alkyl, or deuterated C1-6 alkyl; R2b is H, deuterium, C1-6 alkyl, or deuterated C1-6 alkyl; and the bond between R2a and the carbon atom is a single bond; the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl, or the 8- to 10-membered bicyclic heteroaryl each independently contains one nitrogen atom and optionally 1 or 2 heteroatom(s) independently selected from N, O, and S as ring atoms; and the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from group S1; or
the R2 is
is 3- to 20-membered heterocyclyl, 5- or 6-membered monocyclic heteroaryl, or 8- to 10-membered bicyclic heteroaryl containing one nitrogen atom and attached to other moieties of a molecule through the nitrogen atom;
further optionally contains 1 or 2 heteroatom(s) independently selected from N, O, and S as ring atoms; the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from group S1;
is phenyl or 5- or 6-membered monocyclic heteroaryl; the 5- or 6-membered monocyclic heteroaryl contains 1, 2, or 3 heteroatom(s) independently selected from N, O, and S as ring atoms; the phenyl and the 5- or 6-membered monocyclic heteroaryl are each independently optionally substituted with m2 R3 group(s);
m2 is 1, 2, 3, or 4; each R3 is independently selected from the group consisting of H, oxo (═O), halogen, cyano, hydroxyl, carboxyl, nitro, C1-6 alkyl, C1-6 alkoxy, C3-20 cycloalkyl, 3- to 20-membered heterocyclyl, C6-14 aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, —O—C3-20 cycloalkyl, —O-3- to 20-membered heterocyclyl, —O—C6-14 aryl, —O-5- or 6-membered monocyclic heteroaryl, —O-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-hydroxyl, —C1-4 alkyl-cyano, —C1-4 alkyl-C1-6 alkyl, —C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-C3-20 cycloalkyl, —C1-4 alkyl-O—C3-20 cycloalkyl, —C1-4 alkyl-3- to 20-membered heterocyclyl, —C1-4 alkyl-O-3- to 20-membered heterocyclyl, —C1-4 alkyl-C6-14 aryl, —C1-4 alkyl-O—C6-14 aryl, —C1-4 alkyl-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-O-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-O-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-NRaRb, —C1-4 alkyl-C(═O)—NRaRb, —C1-4 alkyl-NRd—C(═O)—Rc, —C1-4 alkyl-NRd—C(═O)—NRaRb, —C1-4 alkyl-S(═O)2—Rc, —C1-4 alkyl-NRd—S(═O)2—Rc, —C1-4 alkyl-S(═O)2—NRaRb, —C1-4 alkyl-NRd—S(═O)2—NRaRb, —C1-4 alkyl-carboxy, —C(═O)—C1-6 alkyl, —C(═O)O—C1-6 alkyl, —C(═O)—C1-4 alkyl-hydroxy, —C(═O)—C1-4 alkyl-C1-6 alkoxy, —C(═O)—C1-4 alkyl-O—C3-20 cycloalkyl, —C(═O)—C3-20 cycloalkyl, —C(═O)O—C3-20 cycloalkyl, —C(═O)O—C3-20 cycloalkyl, —C(═O)—C1-4 alkyl-C3-20 cycloalkyl, —C(═O)-3- to 20-membered heterocyclyl, —C(═O)—C1-4 alkyl-3- to 20-membered heterocyclyl, —C(═O)—C6-14 aryl, —C(═O)-5- or 6-membered monocyclic heteroaryl, —C(═O)-8- to 10-membered bicyclic heteroaryl, —C(═O)—NRaRb, —NRd—C(═O)—Rc, —NRd—C(═O)—NRaRb, —S(═O)2—Rc, —NRd—S(═O)2—Rc, —S(═O)2—NRaRb, —NRd—S(═O)2—NRaRb, —NRaRb, —ORc, —C1-4 alkyl-P(═O)(C1-6 alkyl)2, —P(═O)(C1-6 alkyl)2; wherein the C1-6 alkyl and the C1-6 alkoxy are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from halogen, deuterium, cyano, 5- to 6-membered heterocyclyl, and hydroxyl; the C3-20 cycloalkyl, the 3- to 20-membered heterocyclyl, the C6-14 aryl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from group S2; the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl each independently contains 1, 2, 3, or 4 heteroatom(s) independently selected from N, O, and S as ring atoms; or
is C5-7 monocyclic cycloalkyl or 5-, 6- or 7-membered monocyclic heterocyclyl; the 5-, 6- or 7-membered heterocyclyl each independently contains 1, 2, or 3 heteroatom(s) independently selected from N, O, and S as ring atoms; the C5-7 monocyclic cycloalkyl and the 5-, 6- or 7-membered monocyclic heterocyclyl are each independently optionally substituted with m2 R3 group(s);
m2 is 1, 2, 3, or 4; each R3 is independently selected from the group consisting of H, oxo (═O), halogen, cyano, hydroxyl, carboxyl, nitro, C1-6 alkyl, C1-6 alkoxy, C3-20 cycloalkyl, 3- to 20-membered heterocyclyl, C6-14 aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, —O—C3-20 cycloalkyl, —O-3- to 20-membered heterocyclyl, —O—C6-14 aryl, —O-5- or 6-membered monocyclic heteroaryl, —O-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-hydroxyl, —C1-4 alkyl-cyano, —C1-4 alkyl-C1-6 alkyl, —C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-C3-20 cycloalkyl, —C1-4 alkyl-O—C3-20 cycloalkyl, —C1-4 alkyl-3- to 20-membered heterocyclyl, —C1-4 alkyl-O-3- to 20-membered heterocyclyl, —C1-4 alkyl-C6-14 aryl, —C1-4 alkyl-O—C6-14 aryl, —C1-4 alkyl-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-O-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-O-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-NRaRb, —C1-4 alkyl-C(═O)—NRaRb, —C1-4 alkyl-NRd—C(═O)—Rc, —C1-4 alkyl-NRd—C(═O)—NRaRb, —C1-4 alkyl-S(═O)2—Rc, —C1-4 alkyl-NRd—S(═O)2—Rc, —C1-4 alkyl-S(═O)2—NRaRb, —C1-4 alkyl-NRd—S(═O)2—NRaRb, —C1-4 alkyl-carboxy, —C(═O)—C1-6 alkyl, —C(═O)O—C1-6 alkyl, —C(═O)—C1-4 alkyl-hydroxy, —C(═O)—C1-4 alkyl-C1-6 alkoxy, —C(═O)—C1-4 alkyl-O—C3-20 cycloalkyl, —C(═O)—C3-20 cycloalkyl, —C(═O)O—C3-20 cycloalkyl, —C(═O)—C1-4 alkyl-C3-20 cycloalkyl, —C(═O)-3- to 20-membered heterocyclyl, —C(═O)—C1-4 alkyl-3- to 20-membered heterocyclyl, —C(═O)—C6-14 aryl, —C(═O)-5- or 6-membered monocyclic heteroaryl, —C(═O)-8- to 10-membered bicyclic heteroaryl, —C(═O)—NRaRb, —NRd—C(═O)—Rc, —NRd—C(═O)—NRaRb, —S(═O)2—Rc, —NRd—S(═O)2—Rc, —S(═O)2—NRaRb, —NRd—S(═O)2—NRaRb, —NRaRb, —ORc, —C1-4 alkyl-P(═O)(C1-6 alkyl)2, —P(═O)(C1-6 alkyl)2, ═CR3aR3b; wherein two hydrogen atoms attached to a same carbon atom can be substituted with two R3 groups such that the two R3 groups together with the carbon atom to which the two R3 groups are attached form a C3-6 monocyclic cycloalkyl group or a 3- to 6-membered monocyclic heterocyclyl group; or two hydrogen atoms attached to different carbon atoms are substituted with two R3 groups, and the two R3 groups join to form —CH2—, —CH2CH2—, or —CH2CH2CH2—; wherein the C1-6 alkyl and the C1-6 alkoxy are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from halogen, deuterium, cyano, 5- to 6-membered heterocyclyl, and hydroxyl; the C3-20 cycloalkyl, the 3- to 20-membered heterocyclyl, the C6-14 aryl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from group S2; the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl each independently contains 1, 2, 3, or 4 heteroatom(s) independently selected from N, O, and S as ring atoms;
wherein R3a and R3b are each independently hydrogen, halogen, cyano, C1-6 alkyl, halogenated C1-6 alkyl, C6-14 aryl, or 5- or 6-membered monocyclic heteroaryl; the C6-14 aryl or the 5- or 6-membered monocyclic heteroaryl is optionally substituted with 1, 2, or 3 group(s) selected from halogen, cyano, C1-4 alkyl, C1-4 alkoxy, halogenated C1-4 alkyl, halogenated C1-4 alkoxy; or R3a and R3b together with the carbon atom to which the R3a and R3b are attached form a C3-6 monocyclic cycloalkyl group or a 3- to 6-membered monocyclic heterocyclyl group; the C3-6 monocyclic cycloalkyl or the 3- to 6-membered monocyclic heterocyclyl is optionally substituted with 1, 2, or 3 group(s) selected from halogen, cyano, C1-4 alkyl, C1-4 alkoxy, halogenated C1-4 alkyl, halogenated C1-4 alkoxy, C6-14 aryl, 5- or 6-membered monocyclic heteroaryl;
is 5- to 7-membered heteroaromatic ring; wherein the m3 hydrogen atom(s) of
are optionally substituted with m3 R4′ group(s); m3 is 1, 2, 3, or 4; R4′ is selected from the group consisting of H, oxo (C═O), halogen, cyano, hydroxyl, carboxyl, nitro, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C3-20 cycloalkyl, 3- to 20-membered heterocyclyl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, —C≡C—C3-20 cycloalkyl, —C≡C-3- to 20-membered heterocyclyl, —C≡C—C6-14 aryl, —C≡C-5- or 6-membered monocyclic heteroaryl, —C≡C-8- to 10-membered bicyclic heteroaryl, —C≡C—C(═O)—NRaRb, —C≡C—C1-4 alkyl-C(═O)—NRaRb, —C1-4 alkyl-hydroxy, —C1-4 alkyl-cyano, —C1-4 alkyl-carboxy, —C1-4 alkyl-C1-6 alkyl, —C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-C3-20 cycloalkyl, —C1-4 alkyl-O—C3-20 cycloalkyl, —C1-4 alkyl-3- to 20-membered heterocyclyl, —C1-4 alkyl-O-3- to 20-membered heterocyclyl, —C1-4 alkyl-C6-14 aryl, —C1-4 alkyl-O—C6-14 aryl, —C1-4 alkyl-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-O-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-O-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-NRaRb—C1-4 alkyl-C(═O)—NRaRb, —C1-4 alkyl-NRd—C(═O)—Rc, —C1-4 alkyl-NRd—C(═O)—NRaRb, —C1-4 alkyl-S(═O)2—Rc, —C1-4 alkyl-NRd—S(═O)2—Rc, —C1-4 alkyl-S(═O)2—NRaRb, —C1-4 alkyl-NRd—S(═O)2—NRaRb, —C(═O)—C1-6 alkyl, —C(═O)—C3-20 cycloalkyl, —C(═O)-3- to 20-membered heterocyclyl, —C(═O)—C6-14 aryl, —C(═O)-5- or 6-membered monocyclic heteroaryl, —C(═O)-8- to 10-membered bicyclic heteroaryl, —C(═O)—NRaRb, —NRd—C(═O)—Rc, —NRd—C(═O)—NRaRb, —S(═O)2—Rc, —NRd—S(═O)2—Rc, —S(═O)2—NRaRb, —NRd—S(═O)2—NRaRb, —NRaRb, —ORc, —C1-4 alkyl-P(═O)—(C1-6 alkyl)2, —P(═O)—(C1-6 alkyl)2; wherein the C1-6 alkyl, the C1-6 alkoxy, the C2-6 alkenyl, and the C2-6 alkynyl are each independently optionally substituted with 1, 2, or 3 group(s) selected from halogen, deuterium, cyano, or hydroxyl; the C3-20 cycloalkyl, the 3- to 20-membered heterocyclyl, the C6-14 aryl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from group S1; the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl each independently contains 1, 2, 3, or 4 heteroatom(s) independently selected from N, O, and S as ring atoms; or
is 5- to 7-membered heterocyclic ring; wherein the m3 hydrogen atom(s) of
are optionally substituted with m3 R4′ group(s); m3 is 1, 2, 3, or 4; R4′ is selected from the group consisting of H, oxo (C═O), halogen, cyano, hydroxyl, carboxyl, nitro, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C3-20 cycloalkyl, 3- to 20-membered heterocyclyl, C6-14 aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, —C≡C—C3-20 cycloalkyl, —C≡C-3- to 20-membered heterocyclyl, —C≡C—C6-14 aryl, —C≡C-5- or 6-membered monocyclic heteroaryl, —C≡C-8- to 10-membered bicyclic heteroaryl, —C≡C—C(═O)—NRaRb, —C≡C—C1-4 alkyl-C(═O)—NRaRb, —C1-4 alkyl-hydroxy, —C1-4 alkyl-cyano, —C1-4 alkyl-carboxy, —C1-4 alkyl-C1-6 alkyl, —C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-C3-20 cycloalkyl, —C1-4 alkyl-O—C3-20 cycloalkyl, —C1-4 alkyl-3- to 20-membered heterocyclyl, —C1-4 alkyl-O-3- to 20-membered heterocyclyl, —C1-4 alkyl-C6-14 aryl, —C1-4 alkyl-O—C6-14 aryl, —C1-4 alkyl-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-O-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-O-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-NRaRb, —C1-4 alkyl-C(═O)—NRaRb, —C1-4 alkyl-NRd—C(═O)—Rc, —C1-4 alkyl-NRd—C(═O)—NRaRb, —C1-4 alkyl-S(═O)2—Rc, —C1-4 alkyl-NRd—S(═O)2—Rc, —C1-4 alkyl-S(═O)2—NRaRb, —C1-4 alkyl-NRd—S(═O)2—NRaRb, —C(═O)—C1-6 alkyl, —C(═O)—C3-20 cycloalkyl, —C(═O)-3- to 20-membered heterocyclyl, —C(═O)—C6-14 aryl, —C(═O)-5- or 6-membered monocyclic heteroaryl, —C(═O)-8- to 10-membered bicyclic heteroaryl, —C(═O)—NRaRb, —NRd—C(═O)—Rc, —NRd—C(═O)—NRaRb, —S(═O)2—Rc, —NRd—S(═O)2—Rc, —S(═O)2—NRaRb, —NRd—S(═O)2—NRaRb, —NRaRb, —ORc, —C1-4 alkyl-P(═O)—(C1-6 alkyl)2, —P(═O)—(C1-6 alkyl)2; the C1-6 alkyl, the C1-6 alkoxy, the C2-6 alkenyl, and the C2-6 alkynyl are each independently optionally substituted with 1, 2, or 3 group(s) selected from halogen, deuterium, cyano, or hydroxyl; the C3-20 cycloalkyl, the 3- to 20-membered heterocyclyl, the C6-14 aryl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from group S1; the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl each independently contains 1, 2, 3, or 4 heteroatom(s) independently selected from N, O, and S as ring atoms;
among the above groups, each group from group S1 is independently selected from the group consisting of oxo (═O), halogen, cyano, hydroxyl, carboxyl, nitro, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C3-20 cycloalkyl, 3- to 20-membered heterocyclyl, C6-14 aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, —O—C3-20 cycloalkyl, —O-3- to 20-membered heterocyclyl, —O—C6-14 aryl, —O-5- or 6-membered monocyclic heteroaryl, —O-8- to 10-membered bicyclic heteroaryl, —C≡C—C3-20 cycloalkyl, —C≡C-3- to 20-membered heterocyclyl, —C≡C—C6-14 aryl, —C≡C-5- or 6-membered monocyclic heteroaryl, —C≡C-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-hydroxy, —C1-4 alkyl-cyano, —C1-4 alkyl-C1-6 alkyl, —C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-C3-20 cycloalkyl, —C1-4 alkyl-O—C3-20 cycloalkyl, —C1-4 alkyl-3- to 20-membered heterocyclyl, —C1-4 alkyl-O-3- to 20-membered heterocyclyl, —C1-4 alkyl-C6-14 aryl, —C1-4 alkyl-O—C6-14 aryl, —C1-4 alkyl-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-O-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-O-8- to 10-membered bicyclic heteroaryl, —S(═O)2—C1-6 alkyl, —S(═O)2—C3-20 cycloalkyl, —S(═O)2-3- to 20-membered heterocyclyl, —C(═O)O—C1-6 alkyl, —C(═O)O—C3-20 cycloalkyl, —C(═O)—C1-6 alkyl, —C(═O)—C3-20 cycloalkyl, —C(═O)—C6-14 aryl, —NRa1Rb1, —C(═O)—NRa1Rb1, —ORc1, —C1-4 alkyl-S(═O)2—C1-6 alkyl, —C1-4 alkyl-S(═O)2—C3-20 cycloalkyl, —C1-4 alkyl-S(═O)2-3- to 20-membered heterocyclyl, —C1-4 alkyl-C(═O)O—C1-6 alkyl, —C1-4 alkyl-C(═O)O—C3-20 cycloalkyl, —C1-4 alkyl-C(═O)—C1-6 alkyl, —C1-4 alkyl-C(═O)—C3-20 cycloalkyl, —C1-4 alkyl-C(═O)—C6-14 aryl, —C(═O)-5- or 6-membered monocyclic heteroaryl, —C(═O)-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-NRa1Rb1, —C1-4 alkyl-C(═O)—NRa1Rb1, —C≡C—C(═O)—NRa1Rb1, —C≡C—C1-4 alkyl-C(═O)—NRa1Rb1, —C1-4 alkyl-ORc1, —C1-4 alkyl-P(═O)—(C1-6 alkyl)2, —P(═O)—(C1-6 alkyl)2, —C1-4 alkyl-NRd1—C(═O)—Rc1, —C1-4 alkyl-NRd1—C(═O)—NRa1Rb1, —C1-4 alkyl-NRd1—S(═O)2—Rc1, —C1-4 alkyl-S(═O)2—NRa1Rb1, —C1-4 alkyl-NRd1—S(═O)2—NRa1Rb1, —NRd1—C(═O)—Rc1, —NRd1—C(═O)—NRa1Rb1, —NRd1—S(═O)2—Rc1, —S(═O)2—NRa1Rb1, —NRd1—S(═O)2—NRa1Rb1; wherein the C1-6 alkyl, the C1-6 alkoxy, the C2-6 alkenyl, and the C2-6 alkynyl are each independently optionally substituted with 1, 2, or 3 group(s) selected from halogen, deuterium, cyano, or hydroxyl; the C3-20 cycloalkyl, the 3- to 20-membered heterocyclyl, the C6-14 aryl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from group S3; the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl each independently contains 1, 2, 3, or 4 heteroatom(s) independently selected from N, O, and S as ring atoms;
among the above groups, each group from group S2 is independently selected from the group consisting of oxo (═O), halogen, cyano, hydroxyl, carboxyl, nitro, C1-6 alkyl, C2-6 alkynyl, C1-6 alkoxy, C3-20 cycloalkyl, 3- to 20-membered heterocyclyl, C6-14 aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, —O-3- to 20-membered heterocyclyl, —O-5- or 6-membered monocyclic heteroaryl, —O-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-hydroxyl, —C1-4 alkyl-cyano, —C1-4 alkyl-C1-6 alkyl, —C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-C3-20 cycloalkyl, —C1-4 alkyl-O—C3-20 cycloalkyl, —C1-4 alkyl-3- to 20-membered heterocyclyl, —C1-4 alkyl-O-3- to 20-membered heterocyclyl, —C1-4 alkyl-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-O-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-O-8- to 10-membered bicyclic heteroaryl, —S(═O)2—C1-6 alkyl, —S(═O)2—C3-20 cycloalkyl, —S(═O)2-3- to 20-membered heterocyclyl, —S(═O)2-5- or 6-membered monocyclic heteroaryl, —S(═O)2-8- to 10-membered bicyclic heteroaryl, —C(═O)O—C1-6 alkyl, —C(═O)O—C3-20 cycloalkyl, —C(═O)O-3- to 20-membered heterocyclyl, —C(═O)O-5- or 6-membered monocyclic heteroaryl, —C(═O)O-8- to 10-membered bicyclic heteroaryl, —NRa1Rb1, —C(═O)—NRa1Rb1, —ORc1, —C1-4 alkyl-C(═O)O—C1-6 alkyl, —C1-4 alkyl-C(═O)O—C3-20 cycloalkyl, —C1-4 alkyl-NRa1Rb1, —C1-4 alkyl-C(═O)—NRa1Rb1, —C≡C—C(═O)—NRa1Rb1, —C≡C—C1-4 alkyl-C(═O)—NRa1Rb1, —C1-4 alkyl-ORc1, —C1-4 alkyl-P(═O)—(C1-6 alkyl)2, —P(═O)—(C1-6 alkyl)2, —C1-4 alkyl-NRd1—C(═O)—Rc1, —C1-4 alkyl-NRd1—C(═O)—NRa1Rb1, —C1-4 alkyl-NRd1—S(═O)2—Rc1, —C1-4 alkyl-S(═O)2—NRa1Rb1, —C1-4 alkyl-NRd1—S(═O)2—NRa1Rb1, —NRd1—C(═O)—Rc1, —NRd1—C(═O)—NRa1Rb1, —NRd1—S(═O)2—Rc1, —S(═O)2—NRa1Rb1, —NRd1—S(═O)2—NRa1Rb1; wherein the C1-6 alkyl, the C1-6 alkoxy, and the C2-6 alkynyl are each independently optionally substituted with 1, 2, or 3 group(s) selected from halogen, deuterium, cyano, or hydroxyl; the C3-20 cycloalkyl, the 3- to 20-membered heterocyclyl, the C6-14 aryl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from group S3; the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl each independently contains 1, 2, 3, or 4 heteroatom(s) independently selected from N, O, and S as ring atoms;
among the above groups, each Ra, Rb, Ra1, and Rb1 is independently H, C1-6 alkyl, halogenated C1-6 alkyl, deuterated C1-6 alkyl, —C1-4 alkyl-hydroxy, —C1-4 alkyl-cyano, —C1-4 alkyl-halogenated C1-6 alkyl, —C1-4 alkyl-deuterated C1-6 alkyl, —C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-halogenated C1-6 alkoxy, —C1-4 alkyl-deuterated C1-6 alkoxy, C3-6 monocyclic cycloalkyl, —C1-4 alkyl-C3-6 monocyclic cycloalkyl, —C1-4 alkyl-O—C3-6 monocyclic cycloalkyl, 3- to 6-membered monocyclic heterocyclyl, —C1-4 alkyl-3- to 6-membered monocyclic heterocyclyl, —C1-4 alkyl-O-3- to 6-membered monocyclic heterocyclyl, phenyl, —C1-4 alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-8- to 10-membered bicyclic heteroaryl, —S(═O)2—C1-6 alkyl, —S(═O)2—C3-6 monocyclic cycloalkyl, —S(═O)2-3- to 6-membered monocyclic heterocyclyl, —C(═O)—C1-6 alkyl, —C(═O)—C3-6 monocyclic cycloalkyl, —C(═O)-3- to 6-membered monocyclic heterocyclyl; wherein the C3-6 monocyclic cycloalkyl, the 3- to 6-membered monocyclic heterocyclyl, the phenyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are optionally substituted with 1 or 2 group(s) selected from the group consisting of halogen, hydroxyl, carboxyl, nitro, C1-6 alkyl, halogenated C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkoxy, deuterated C1-6 alkoxy, —NH2, —NHC1-6 alkyl, —N(C1-6 alkyl)2, —C1-4 alkyl-P(═O)—(C1-6 alkyl)2, —P(═O)—(C1-6 alkyl)2; or
each Ra and Rb together with the nitrogen atom to which the Ra and Rb are attached form a 3- to 20-membered heterocyclyl group; each Ra1 and Rb1 together with the nitrogen atom to which the Ra1 and Rb1 are attached form a 3- to 20-membered heterocyclyl group; wherein the 3- to 20-membered heterocyclyl is each independently optionally substituted with 1 or 2 group(s) selected from the group consisting of halogen, hydroxyl, carboxyl, nitro, C1-6 alkyl, halogenated C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkoxy, deuterated C1-6 alkoxy, —NH2, —NHC1-6 alkyl, —N(C1-6 alkyl)2, —C1-4 alkyl-P(═O)—(C1-6 alkyl)2, —P(═O)—(C1-6 alkyl)2;
among the above groups, each Rd and Rd1 are independently H, C1-6 alkyl, or deuterated C1-6 alkyl;
among the above groups, each Rc and Rc1 are independently H, C1-6 alkyl, halogenated C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkoxy, deuterated C1-6 alkoxy, —C1-4 alkyl-halogenated C1-6 alkyl, —C1-4 alkyl-deuterated C1-6 alkyl, —C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-halogenated C1-6 alkoxy, —C1-4 alkyl-deuterated C1-6 alkoxy, C3-6 monocyclic cycloalkyl, —C1-4 alkyl-C3-6 monocyclic cycloalkyl, —C1-4 alkyl-O—C3-6 monocyclic cycloalkyl, 3- to 6-membered monocyclic heterocyclyl, —C1-4 alkyl-3- to 6-membered monocyclic heterocyclyl, —C1-4 alkyl-O-3- to 6-membered monocyclic heterocyclyl, phenyl, —C1-4 alkyl-phenyl, 5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, or —C1-4 alkyl-8- to 10-membered bicyclic heteroaryl; the C3-6 monocyclic cycloalkyl, the 3- to 6-membered monocyclic heterocyclyl, the phenyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are optionally substituted with 1 or 2 group(s) selected from the group consisting of halogen, hydroxyl, carboxyl, nitro, C1-6 alkyl, halogenated C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkoxy, deuterated C1-6 alkoxy, —NH2, —NHC1-6 alkyl, —N(C1-6 alkyl)2, —C1-4 alkyl-P(═O)—(C1-6 alkyl)2, —P(═O)—(C1-6 alkyl)2;
among the above groups, each group from group S3 is independently selected from the group consisting of oxo (C═O), halogen, cyano, hydroxy, carboxy, nitro, C1-6 alkyl, halogenated C1-6 alkyl, deuterated C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkoxy, deuterated C1-6 alkoxy, —NH2, —NHC1-6 alkyl, —N(C1-6 alkyl)2, —C1-4 alkyl-P(═O)—(C1-6 alkyl)2, —P(═O)—(C1-6 alkyl)2, 3- to 6-membered monocyclic heterocyclyl;
among the above groups, the —C1-4 alkyl- or the —C3-6 monocyclic cycloalkyl- is unsubstituted, or hydrogen atoms of the —C1-4 alkyl- are each independently substituted with a group selected from halogen, cyano, hydroxy, C1-6 alkyl, halogenated C1-6 alkyl, deuterated C1-6 alkyl, —CH2-hydroxy, —CH2-cyano, and phenyl, or two hydrogen atoms attached to a same carbon atom of the C1-4 alkyl are simultaneously substituted with —(CH2)j— to form a cycloalkyl group, wherein j is 2, 3, 4, 5, or 6; hydrogen atoms of the —C3-6 monocyclic cycloalkyl- are each independently substituted with a group selected from halogen, cyano, hydroxy, C1-6 alkyl, halogenated C1-6 alkyl, deuterated C1-6 alkyl.

### Claim 8 (depends on 7)

The compound, or the pharmaceutically acceptable salt, the stereoisomer, the solvate or the prodrug thereof of claim 7, wherein the compound is a compound of formula (IC1);
wherein
X, Y,
R2, m1,
R3, and m2 are as defined in claim 7;
B1 is CH or N;
R4′ is selected from the group consisting of H, oxo (C═O), halogen, cyano, hydroxyl, carboxyl, nitro, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C3-20 cycloalkyl, 3- to 20-membered heterocyclyl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, —C≡C—C3-20 cycloalkyl, —C≡C-3- to 20-membered heterocyclyl, —C≡C—C6-14 aryl, —C≡C-5- or 6-membered monocyclic heteroaryl, —C≡C-8- to 10-membered bicyclic heteroaryl, —C≡C—C(═O)—NRaRb, —C≡C—C1-4 alkyl-C(═O)—NRaRb, —C1-4 alkyl-hydroxy, —C1-4 alkyl-cyano, —C1-4 alkyl-carboxy, —C1-4 alkyl-C1-6 alkyl, —C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-C3-20 cycloalkyl, —C1-4 alkyl-O—C3-20 cycloalkyl, —C1-4 alkyl-3- to 20-membered heterocyclyl, —C1-4 alkyl-O-3- to 20-membered heterocyclyl, —C1-4 alkyl-C6-14 aryl, —C1-4 alkyl-O—C6-14 aryl, —C1-4 alkyl-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-O-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-O-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-NRaRb, —C1-4 alkyl-C(═O)—NRaRb, —C1-4 alkyl-NRd—C(═O)—Rc, —C1-4 alkyl-NRd—C(═O)—NRaRb, —C1-4 alkyl-S(═O)2—Rc, —C1-4 alkyl-NRd—S(═O)2—Rc, —C1-4 alkyl-S(═O)2—NRaRb, —C1-4 alkyl- NRd—S(═O)2—NRaRb, —C(═O)—C1-6 alkyl, —C(═O)—C3-20 cycloalkyl, —C(═O)-3- to 20-membered heterocyclyl, —C(═O)—C6-14 aryl, —C(═O)-5- or 6-membered monocyclic heteroaryl, —C(═O)-8- to 10-membered bicyclic heteroaryl, —C(═O)—NRaRb, —NRd—C(═O)—Rc, —NRd—C(═O)—NRaRb, —S(═O)2—Rc, —NRd—S(═O)2—Rc, —S(═O)2—NRaRb, —NRd—S(═O)2—NRaRb, —NRaRb, —ORc, —C1-4 alkyl-P(═O)—(C1-6 alkyl)2, —P(═O)—(C1-6 alkyl)2; wherein the C1-6 alkyl, the C1-6 alkoxy, the C2-6 alkenyl, and the C2-6 alkynyl are each independently optionally substituted with 1, 2, or 3 group(s) selected from halogen, deuterium, cyano, or hydroxyl; the C3-20 cycloalkyl, the 3- to 20-membered heterocyclyl, the C6-14 aryl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from group S1; the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl each independently contains 1, 2, 3, or 4 heteroatom(s) independently selected from N, O, and S as ring atoms;
wherein Ra, Rb, Rc, Rd, and group S1 are each as defined in claim 7.

### Claim 9 (depends on 8)

The compound, or the pharmaceutically acceptable salt, the stereoisomer, the solvate or the prodrug thereof of claim 8, wherein the compound is a compound of formula (IC1a), a compound of formula (IC1b), a compound of formula (IC1c), a compound of formula (IC1d), a compound of formula (IC1e), or a compound of formula (IC1f);
in each formula, X, Y, R2,
R3, m2, B1, and R4′ are each independently as defined in claim 8.

### Claim 10 (depends on 7)

The compound, or the pharmaceutically acceptable salt, the stereoisomer, the solvate or the prodrug thereof of claim 7, wherein the compound is a compound of formula (IC3);
wherein X, Y,
R2, m1,
R3, and m2 are as defined in claim 7; B2 is N or CH;
R4′ is selected from the group consisting of H, oxo (C═O), halogen, cyano, hydroxyl, carboxyl, nitro, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C3-20 cycloalkyl, 3- to 20-membered heterocyclyl, C6-14 aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, —C≡C—C3-20 cycloalkyl, —C≡C-3- to 20-membered heterocyclyl, —C≡C—C6-14 aryl, —C≡C-5- or 6-membered monocyclic heteroaryl, —C≡C-8- to 10-membered bicyclic heteroaryl, —C≡C—C(═O)—NRaRb, —C≡C—C1-4 alkyl-C(═O)—NRaRb, —C1-4 alkyl-hydroxy, —C1-4 alkyl-cyano, —C1-4 alkyl-carboxy, —C1-4 alkyl-C1-6 alkyl, —C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-C3-20 cycloalkyl, —C1-4 alkyl-O—C3-20 cycloalkyl, —C1-4 alkyl-3- to 20-membered heterocyclyl, —C1-4 alkyl-O-3- to 20-membered heterocyclyl, —C1-4 alkyl-C6-14 aryl, —C1-4 alkyl-O—C6-14 aryl, —C1-4 alkyl-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-O-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-O-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-NRaRb, —C1-4 alkyl-C(═O)—NRaRb, —C1-4 alkyl-NRd—C(═O)—Rc, —C1-4 alkyl-NRd—C(═O)—NRaRb, —C1-4 alkyl-S(═O)2—Rc, —C1-4 alkyl-NRd—S(═O)2—Rc, —C1-4 alkyl-S(═O)2—NRaRb, —C1-4 alkyl-NRd—S(═O)2—NRaRb, —C(═O)—C1-6 alkyl, —C(═O)—C3-20 cycloalkyl, —C(═O)-3- to 20-membered heterocyclyl, —C(═O)—C6-14 aryl, —C(═O)-5- or 6-membered monocyclic heteroaryl, —C(═O)-8- to 10-membered bicyclic heteroaryl, —C(═O)—NRaRb, —NRd—C(═O)—Rc, —NRd—C(═O)—NRaRb, —S(═O)2—Rc, —NRd—S(═O)2—Rc, —S(═O)2—NRaRb, —NRd—S(═O)2—NRaRb, —NRaRb, —ORc, —C1-4 alkyl-P(═O)—(C1-6 alkyl)2, —P(═O)—(C1-6 alkyl)2; the C1-6 alkyl, the C1-6 alkoxy, the C2-6 alkenyl, and the C2-6 alkynyl are each independently optionally substituted with 1, 2, or 3 group(s) selected from halogen, deuterium, cyano, or hydroxyl; the C3-20 cycloalkyl, the 3- to 20-membered heterocyclyl, the C6-14 aryl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from group S1; the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl each independently contains 1, 2, 3, or 4 heteroatom(s) independently selected from N, O, and S as ring atoms;
wherein Ra, Rb, Rc, Rd, and group S1 are each as defined in claim 7.

### Claim 11 (depends on 10)

The compound, or the pharmaceutically acceptable salt, the stereoisomer, the solvate or the prodrug thereof of claim 10, wherein the compound is a compound of formula (IC3a), a compound of formula (IC3b), a compound of formula (IC3c), a compound of formula (IC3d), a compound of formula (IC3e), or a compound of formula (IC3f);
in each formula, X, Y, R2,
R3, m2, B2, and R4′ are each independently as defined in claim 10.

### Claim 12 (depends on 7)

The compound, or the pharmaceutically acceptable salt, the stereoisomer, the solvate or the prodrug thereof of claim 7, wherein the compound is a compound of formula (IC4);
wherein X, Y,
R2, m1,
R3, and m2 are as defined in claim 7; B3 is CHR4′″, NR4′″, or O;
R4′, R4″, and R4′″ are each independently selected from the group consisting of H, oxo (C═O), halogen, cyano, hydroxyl, carboxyl, nitro, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C3-20 cycloalkyl, 3- to 20-membered heterocyclyl, C6-14 aryl, 5- or 6-membered monocyclic heteroaryl, 8- to 10-membered bicyclic heteroaryl, —C≡C—C3-20 cycloalkyl, —C≡C-3- to 20-membered heterocyclyl, —C≡C—C6-14 aryl, —C≡C-5- or 6-membered monocyclic heteroaryl, —C≡C-8- to 10-membered bicyclic heteroaryl, —C≡C—C(═O)—NRaRb, —C≡C—C1-4 alkyl-C(═O)—NRaRb, —C1-4 alkyl-hydroxy, —C1-4 alkyl-cyano, —C1-4 alkyl-carboxy, —C1-4 alkyl-C1-6 alkyl, —C1-4 alkyl-C1-6 alkoxy, —C1-4 alkyl-C3-20 cycloalkyl, —C1-4 alkyl-O—C3-20 cycloalkyl, —C1-4 alkyl-3- to 20-membered heterocyclyl, —C1-4 alkyl-O-3- to 20-membered heterocyclyl, —C1-4 alkyl-C6-14 aryl, —C1-4 alkyl-O—C6-14 aryl, —C1-4 alkyl-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-O-5- or 6-membered monocyclic heteroaryl, —C1-4 alkyl-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-O-8- to 10-membered bicyclic heteroaryl, —C1-4 alkyl-NRaRb, —C1-4 alkyl-C(═O)—NRaRb, —C1-4 alkyl-NRd—C(═O)—Rc, —C1-4 alkyl-NRd—C(═O)—NRaRb, —C1-4 alkyl-S(═O)2—Rc, —C1-4 alkyl-NRd—S(═O)2—Rc, —C1-4 alkyl-S(═O)2—NRaRb, —C1-4 alkyl-NRd—S(═O)2—NRaRb, —C(═O)—C1-6 alkyl, —C(═O)—C3-20 cycloalkyl, —C(═O)-3- to 20-membered heterocyclyl, —C(═O)—C6-14 aryl, —C(═O)-5- or 6-membered monocyclic heteroaryl, —C(═O)-8- to 10-membered bicyclic heteroaryl, —C(═O)—NRaRb, —NRd—C(═O)—Rc, —NRd—C(═O)—NRaRb, —S(═O)2—Rc, —NRd—S(═O)2—Rc, —S(═O)2—NRaRb, —NRd—S(═O)2—NRaRb, —NRaRb, —ORc, —C1-4 alkyl-P(═O)—(C1-6 alkyl)2, —P(═O)—(C1-6 alkyl)2; the C1-6 alkyl, the C1-6 alkoxy, the C2-6 alkenyl, and the C2-6 alkynyl are each independently optionally substituted with 1, 2, or 3 group(s) selected from halogen, deuterium, cyano, or hydroxyl; the C3-20 cycloalkyl, the 3- to 20-membered heterocyclyl, the C6-14 aryl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl are each independently optionally substituted with 1, 2, 3, or 4 group(s) selected from group S1; the 3- to 20-membered heterocyclyl, the 5- or 6-membered monocyclic heteroaryl, and the 8- to 10-membered bicyclic heteroaryl each independently contains 1, 2, 3, or 4 heteroatom(s) independently selected from N, O, and S as ring atoms; or
R4′ and R4″ together with the carbon atom to which the R4′ and R4″ are attached form a carbonyl group (C═O);
wherein Ra, Rb, Rc, Rd, and group S1 are each as defined in claim 7.

### Claim 13 (depends on 12)

The compound, or the pharmaceutically acceptable salt, the stereoisomer, the solvate or the prodrug thereof of claim 12, wherein the compound is a compound of formula (IC4a), a compound of formula (IC4b), a compound of formula (IC4c), a compound of formula (IC4d), a compound of formula (IC4e), or a compound of formula (IC4f);
in each formula, X, Y, R2,
R3, m2, B3, R4′, and R4″ are each independently as defined in claim 12.

### Claim 14 (depends on 7)

The compound, or the pharmaceutically acceptable salt, the stereoisomer, the solvate or the prodrug thereof of claim 7, wherein the compound is selected from the group consisting of

### Claim 15 (depends on 7)

The compound, or the pharmaceutically acceptable salt, the stereoisomer, the solvate or the prodrug thereof of claim 7, wherein the compound is selected from Table (Q.

### Claim 16 (depends on 7)

A pharmaceutical composition comprising the compound, or the pharmaceutically acceptable salt, the stereoisomer, the solvate or the prodrug thereof of claim 7; and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 7)

A method for preventing and/or treating a disease or condition associated with HPK1 activity, comprising administering to an individual in need thereof:
the compound, or the pharmaceutically acceptable salt, the stereoisomer, the solvate or the prodrug thereof of claim 7, or
a pharmaceutical composition comprising: the compound, or the pharmaceutically acceptable salt, the stereoisomer, the solvate or the prodrug thereof of claim 7; and a pharmaceutically acceptable carrier.

### Claim 18 (depends on 17)

The method of claim 17, wherein the disease or condition associated with HPK1 activity is cancer.
